M. Leontien van der Bent

Ms. M. Leontien van der Bent

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2016 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
GGGiel Göertz
Giel Göertz
JFJ. J. Fros
J. J. Fros
PMP. Miesen
P. Miesen
CVC. B. F. Vogels
C. B. F. Vogels
MBM. Leontien van der Bent
M. Leontien van der Bent
Gorben PijlmanGorben Pijlman
Gorben Pijlman
Flaviviruses, such as Zika virus, yellow fever virus, dengue virus, and West Nile virus (WNV), are a serious concern for human health. Flaviviruses produce an abundant noncoding subgenomic flavivirus RNA (sfRNA) in infected cells. sfRNA results from stalling of the host 5′-3′ exoribonuclease XRN1/Pacman on conserved RNA structures in the 3′ untranslated region (UTR) of the viral genomic RNA. sfRNA production is conserved in insect-specific, mosquito-borne, and tick-borne flaviviruses and flaviviruses with no known vector, suggesting a pivotal role for sfRNA in the flavivirus life cycle. Here, we investigated the function of sfRNA during WNV infection of Culex pipiens mosquitoes and evaluated its role in determining vector competence. An sfRNA1-deficient WNV was generated that displayed growth kinetics similar to those of wild-type WNV in both RNA interference (RNAi)-competent and -compromised mosquito cell lines. Small-RNA deep sequencing of WNV-infected mosquitoes indicated an active small interfering RNA (siRNA)-based antiviral response for both the wild-type and sfRNA1-deficient viruses. Additionally, we provide the first evidence that sfRNA is an RNAi substrate in vivo . Two reproducible small-RNA hot spots within the 3′ UTR/sfRNA of the wild-type virus mapped to RNA stem-loops SL-III and 3′ SL, which stick out of the three-dimensional (3D) sfRNA structure model. Importantly, we demonstrate that sfRNA-deficient WNV displays significantly decreased infection and transmission rates in vivo when administered via the blood meal. Finally, we show that transmission and infection rates are not affected by sfRNA after intrathoracic injection, thereby identifying sfRNA as a key driver to overcome the mosquito midgut infection barrier. This is the first report to describe a key biological function of sfRNA for flavivirus infection of the arthropod vector, providing an explanation for the strict conservation of sfRNA production. IMPORTANCE Understanding the flavivirus transmission cycle is important to identify novel targets to interfere with disease and to aid development of virus control strategies. Flaviviruses produce an abundant noncoding viral RNA called sfRNA in both arthropod and mammalian cells. To evaluate the role of sfRNA in flavivirus transmission, we infected mosquitoes with the flavivirus West Nile virus and an sfRNA-deficient mutant West Nile virus. We demonstrate that sfRNA determines the infection and transmission rates of West Nile virus in Culex pipiens mosquitoes. Comparison of infection via the blood meal versus intrathoracic injection, which bypasses the midgut, revealed that sfRNA is important to overcome the mosquito midgut barrier. We also show that sfRNA is processed by the antiviral RNA interference machinery in mosquitoes. This is the first report to describe a pivotal biological function of sfRNA in arthropods. The results explain why sfRNA production is evolutionarily conserved.

15 May 2015 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
TSTobias Schmid
Tobias Schmid
LSL. Basten Snoek
L. Basten Snoek
EFErika Fröhli
Erika Fröhli
MBM. Leontien van der Bent
M. Leontien van der Bent
Jan KammengaJan Kammenga
Jan Kammenga
AHAlex Hajnal
Alex Hajnal
Human cancer is caused by the interplay of mutations in oncogenes and tumor suppressor genes and inherited variations in cancer susceptibility genes. While many of the tumor initiating mutations are well characterized, the effect of genetic background variation on disease onset and progression is less understood. We have used C. elegans genetics to identify genetic modifiers of the oncogenic RAS/MAPK signaling pathway. Quantitative trait locus analysis of two highly diverged C. elegans isolates combined with allele swapping experiments identified the polymorphic monoamine oxidase A (MAOA) gene amx-2 as a negative regulator of RAS/MAPK signaling. We further show that the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA), which is a product of MAOA catalysis, systemically inhibits RAS/MAPK signaling in different organs of C. elegans. Thus, MAOA activity sets a global threshold for MAPK activation by controlling 5-HIAA levels. To our knowledge, 5-HIAA is the first endogenous small molecule that acts as a systemic inhibitor of RAS/MAPK signaling. Mutations that activate a RAS oncogene are found in a large proportion of human cancers. In this study, we have used the roundworm Caenorhabditis elegans (C. elegans) as a model to investigate how the genetic composition of the animal affects the outcome of oncogenic RAS mutations that activate the MAPK pathway. By comparing the effects of activated RAS/MAPK signaling in two genetically different C. elegans strains, we have identified the monoamine oxidase A (MAOA) gene amx-2 as a negative regulator of RAS/MAPK signaling. MAOA enzymes are primarily known to catalyze the degradation of the neurotransmitters dopamine and serotonin. Here, we show that a specific serotonin degradation product that is produced by MAOA (5-HIAA) inhibits RAS signaling in different organs of C. elegans. Thus, by producing the inhibitory serotonin metabolite 5-HIAA the MAOA enzyme systemically controls the activation of the RAS/MAPK pathway.

Verified
Journal Article
Open access
PDF file
TNT. Truc My Nguyen
T. Truc My Nguyen
MBM. Leontien van der Bent
M. Leontien van der Bent
MWMarieke J. H. Wermer
Marieke J. H. Wermer
IWIdo R. van Den Wijngaard
Ido R. van Den Wijngaard
EZErik W. van Zwet
Erik W. van Zwet
ANAnne Yaël Nossent
Anne Yaël Nossent
Early blood biomarkers to diagnose acute stroke could drastically reduce treatment delays. We investigated whether circulating small non-coding RNAs can serve as biomarkers to distinguish between acute ischemic stroke (IS), intracerebral hemorrhage (ICH) and stroke mimics (SM). In an ongoing observational cohort study, we performed small RNA-sequencing in plasma obtained from a discovery cohort of 26 patients (9 IS, 8 ICH and 9 SM) presented to the emergency department within 6 h of symptom onset. We validated our results in an independent dataset of 20 IS patients and 20 healthy controls. ICH plasma had the highest abundance of ribosomal and tRNA-derived fragments, while microRNAs were most abundant in plasma of IS patients. Combinations of four to five tRNAs yielded diagnostic accuracies (areas under the receiver operating characteristics curve) up to 0.986 (ICH vs. IS and SM) in the discovery cohort. Validation of the IS and SM models in the independent dataset yielded diagnostic accuracies of 0.870 and 0.885 to distinguish IS from healthy controls. Thus, we identified tRNA-derived fragments as a promising novel class of biomarkers to distinguish between acute IS, ICH and SM, as well as healthy controls.

13 May 2014 in Scientific Reports
Verified
Journal Article
Open access
MBM. Leontien van der Bent
M. Leontien van der Bent
MSMark Sterken
Mark Sterken
RVRita J. M. Volkers
Rita J. M. Volkers
JRJoost A. G. Riksen
Joost A. G. Riksen
TSTobias Schmid
Tobias Schmid
LSL. Basten Snoek
L. Basten Snoek
C. elegans is extensively used to study the Wnt-pathway and most of the core-signalling components are known. Four β-catenins are important gene expression regulators in Wnt-signalling. One of these, bar-1, is part of the canonical Wnt-pathway. Together with Wnt effector pop-1, bar-1 forms a transcription activation complex which regulates the transcription of downstream genes. The effects of bar-1 loss-of-function mutations on many phenotypes have been studied well. However, the effects on global gene expression are unknown. Here we report the effects of a loss-of-function mutation bar-1(ga80). By analysing the transcriptome and developmental phenotyping we show that bar-1(ga80) impairs developmental timing. This developmental difference confounds the comparison of the gene expression profile between the mutant and the reference strain. When corrected for this difference it was possible to identify genes that were directly affected by the bar-1 mutation. We show that the Wnt-pathway itself is activated, as well as transcription factors elt-3, pqm-1, mdl-1 and pha-4 and their associated genes. The outcomes imply that this response compensates for the loss of functional bar-1. Altogether we show that bar-1 loss-of function leads to delayed development possibly caused by an induction of a stress response, reflected by daf-16 activated genes.

16 July 2019 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
MBM. Leontien van der Bent
M. Leontien van der Bent
OFOmar Paulino da Silva Filho
Omar Paulino da Silva Filho
MWMarieke Willemse
Marieke Willemse
MHMattias Hällbrink
Mattias Hällbrink
DWDerick G. Wansink
Derick G. Wansink
RBRoland Brock
Roland Brock
Antisense oligonucleotides (ASOs) are a promising class of therapeutics that are starting to emerge in the clinic. Determination of intracellular concentrations required for biologic effects and identification of effective delivery vehicles are crucial for understanding the mode of action and required dosing. Here, we investigated which nuclear oligonucleotide concentration is needed for a therapeutic effect for a triplet repeat‐targeting ASO in a muscle cell model of myotonic dystrophy type 1 (DM1). For cellular delivery, ASOs were complexed into nanoparticles using the cationic cell‐penetrating peptides nona‐arginine and PepFect14 (PF14). Although both peptides facilitated uptake, only PF14 led to a dose‐dependent correction of disease‐typical abnormal splicing. In line with this observation, time‐lapse confocal microscopy demonstrated that only PF14 mediated translocation of the ASOs to the nucleus, which is the main site of action. Through fluorescence lifetime imaging, we could distinguish intact oligonucleotide from free fluorophore, showing that PF14 also shielded the ASOs from degradation. Finally, we employed a combination of live‐cell fluorescence correlation spectroscopy and immunofluorescence microscopy and demonstrated that intranuclear blocking—type oligonucleotide concentrations in the upper nanomolar range were required to dissolve nuclear muscleblind‐like protein 1 foci, a hallmark of DM1. Our findings have important implications for the clinical use of ASOs in DM1 and provide a basis for further research on other types of ASOs.—Van der Bent, M. L., Paulino da Silva Filho, O., Willemse, M., Hällbrink, M., Wansink, D. G., Brock, R. The nuclear concentration required for antisense oligonucleotide activity in myotonic dystrophy cells. FASEB J. 33, 11314–11325 (2019). www.fasebj.org

8 March 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MBM. Leontien van der Bent
M. Leontien van der Bent
OFOmar Paulino da Silva Filho
Omar Paulino da Silva Filho
JLJudith van Luijk
Judith van Luijk
RBRoland Brock
Roland Brock
DWDerick G. Wansink
Derick G. Wansink
Antisense oligonucleotide (AON)-based therapies hold promise for a range of neurodegenerative and neuromuscular diseases and have shown benefit in animal models and patients. Success in the clinic is nevertheless still limited, due to unfavourable biodistribution and poor cellular uptake of AONs. Extensive research is currently being conducted into the formulation of AONs to improve delivery, but thus far there is no consensus on which of those strategies will be the most effective. This systematic review was designed to answer in an unbiased manner which delivery strategies most strongly enhance the efficacy of AONs in animal models of heritable neurodegenerative and neuromuscular diseases. In total, 95 primary studies met the predefined inclusion criteria. Study characteristics and data on biodistribution and toxicity were extracted and reporting quality and risk of bias were assessed. Twenty studies were eligible for meta-analysis. We found that even though the use of delivery systems provides an advantage over naked AONs, it is not yet possible to select the most promising strategies. Importantly, standardisation of experimental procedures is warranted in order to reach conclusions about the most efficient delivery strategies. Our best practice guidelines for future experiments serve as a step in that direction.